Medical Center Medconsult Pleven OOD

The team at Medical Center Medconsult Pleven OOD focuses on improving outcomes for patients with cardiovascular disease and related conditions, exploring both preventive strategies and novel therapeutic options.

• Primary prevention of atherosclerotic events
• Management of heart failure with preserved ejection fraction
• Blood‑clot prevention in atrial fibrillation
• Lipid‑lowering strategies for high‑risk patients
• Evaluation of new anticoagulant agents

With over 118 trials conducted by eight investigators, the site contributes significantly to cardiovascular innovation across Europe.

Investigations target chronic airway diseases and allergic disorders, aiming to reduce exacerbations and improve quality of life for individuals with asthma, chronic obstructive pulmonary disease, and seasonal allergies.

• Severe asthma exacerbation reduction
• Long‑term safety of COPD inhaler regimens
• Allergen immunotherapy for grass pollen allergy
• Management of chronic rhinosinusitis with nasal polyps
• Antiviral therapy for respiratory syncytial virus in adults

The facility’s multidisciplinary approach supports both pediatric and adult populations in the Pleven region.

The center conducts extensive studies on autoimmune and inflammatory skin conditions, evaluating biologic and small‑molecule therapies for diseases such as psoriatic arthritis, atopic dermatitis, and lupus erythematosus.

• Biologic therapy assessment in psoriatic arthritis
• Topical and systemic options for atopic dermatitis
• Urticaria activity score improvement trials
• Cutaneous lupus disease activity monitoring
• Hidradenitis suppurativa treatment investigations

These efforts address both adult and adolescent patients, reflecting the site’s commitment to dermatologic health.

Clinical programs explore therapies for neuro‑degenerative and psychiatric disorders, including multiple sclerosis, Alzheimer’s disease, schizophrenia, and generalized anxiety disorder.

• Relapse reduction in relapsing‑remitting multiple sclerosis
• Agitation management in Alzheimer’s dementia
• Adjunctive treatments for treatment‑resistant schizophrenia
• Novel agents for generalized anxiety disorder
• Cognitive performance enhancement in schizophrenia

The research supports both acute symptom control and long‑term disease modification.

Studies address metabolic dysfunctions, focusing on conditions such as hypertriglyceridemia, obesity‑related cardiovascular risk, and post‑menopausal osteoporosis, as well as rare disorders like exocrine pancreatic insufficiency.

• Lipid‑lowering agents for severe hypertriglyceridemia
• Bone density improvement in osteoporosis
• Management of pancreatic enzyme deficiency
• Weight‑related cardiovascular risk reduction strategies
• Evaluation of novel metabolic biomarkers

These trials aim to enhance metabolic health and reduce associated complications.

The site participates in antiviral and vaccine‑adjunct studies targeting influenza, SARS‑CoV‑2, and respiratory syncytial virus, seeking to improve treatment outcomes for high‑risk populations.

• Antiviral efficacy in COVID‑19
• Treatment of influenza in high‑risk adults
• RSV therapeutic development for older adults
• Safety of novel antivirals in immunocompromised patients
• Vaccine adjunct studies to boost immune response

Ongoing collaborations enhance the center’s capacity to respond to emerging infectious threats.